A recent announcement by Cardio Diagnostics, details a bright future for the company’s AI-driven molecular heart disease tests, which evaluate objective epigenetic and genetic biomarkers in patients suspected to be at risk or who may have coronary heart disease.

After securing an Innovation Technology contract with Vizient, Inc. — the nation’s largest provider-driven healthcare performance improvement company — Cardio Diagnostics will have access to a potential customer base that encompasses greater than 60% of hospitals and 97% of academic medical centers in the United States.